Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Anacor Pharmaceuticals, Inc.
Type
Public
Traded as NASDAQ: ANAC
Industry Pharmaceutical
Fate Acquired by Pfizer
Key people
Paul L. Berns (CEO)
Website anacor.com

Anacor Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. It is based in Palo Alto, California, United States. Anacor was founded in 2002 based on technology created by Lucy Shapiro at Stanford University and Stephen Benkovic at Pennsylvania State University. Cofounder David Perry served as CEO and President from 2002 to 2014, and took the company public in 2010. Since then, the company has generated a pipeline of both topical and systemic boron-based compounds of which five are currently in clinical development.

In May 2016, Pfizer announced it would acquire Anacor Pharmaceuticals for $5.2 billion, expanding the company's portfolio in both inflammation and immunology drugs areas.

Boron is a naturally occurring element in the environment, but relative to carbon, hydrogen, nitrogen and oxygen, little research has been done on the role of boron in therapeutics because of the limited understanding of the physical properties necessary to provide boron-based compounds with the attributes required of pharmaceutical therapies as well as difficulty in chemical synthesis. However, boron has two qualities that give it advantages in the small-molecule drug discovery process. First, boron has a unique geometry that allows compounds made from it to have two distinct shapes, giving boron-based drugs the ability to interact with biological targets in novel ways and to address targets not amenable to intervention by traditional carbon-based compounds. And second, boron's enhanced reactivity as compared to carbon allows the molecules to hit targets that are difficult to inhibit with carbon chemistry.

Tavaborole is a topical antifungal drug for the treatment of onychomycosis, a fungal infection of the nail and nail bed. Anacor began its Phase 3 trials in December 2010. Tavaborole inhibits an essential fungal enzyme, leucyl-transfer RNA synthetase, or LeuRS, required for protein synthesis. The inhibition of protein synthesis leads to termination of cell growth and cell death, eliminating the fungal infection. No treatment-related systemic side effects have been observed in any of its clinical trials. It gained FDA approval in July 2014.

Crisaborole Topical Ointment 2% is a topical anti-inflammatory product for the treatment of psoriasis and atopic dermatitis. Crisaborole Topical Ointment 2% inhibits PDE4 and reduces the production of TNF-alpha, a precursor of the inflammation associated with psoriasis as well as other cytokines, including IL-12 and IL-23, which are proteins believed to be involved in the inflammation process and immune responses. Crisaborole Topical Ointment 2% is currently in Phase 2b for psoriasis and Phase 3 for atopic dermatitis.

Investment goal date:
Dividends reinvested
Anacor Pharmaceuticals, Inc. ANAC report Q1 2016
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q3 2016
2016-11-07
--
--
Q2 2016
2016-08-04
--
--
Q1 2016
2016-05-10
-0.3600
-0.3600
Q4 2015
2016-02-29
-0.4300
-0.4300
Q3 2015
2015-11-03
-0.3700
-0.3700
Q2 2015
2015-08-06
-0.3000
-0.3000
Q1 2015
2015-05-06
-0.3000
-0.3000
Q4 2014
2015-03-12
-0.2400
-0.2400
Q3 2014
2014-11-06
-0.7400
-0.7400
Q2 2014
2014-08-07
-0.5800
-0.5800
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
Apex Capital Management
235567
APIS CAPITAL ADVISORS, LLC
23000
BAIRD ROBERT W & CO INC /WI/
66958
MANAGED ACCOUNT ADVISORS LLC
84541
RUSSELL FRANK CO/
226757
SHAPIRO ROBERT N
26724
Major Shareholders
Name Relationship
Total Shares
Holding stocks
PERRY DAVID P
0.8600% (361306)
ANAC /
RHO VENTURES IV LP
0.5800% (243815)
ANAC / IL /
VENROCK ASSOCIATES IV L P
8.5100% (3575535)
AKAO / ANAC /
VENROCK ASSOCIATES V LP
8.8700% (3725535)
Parker Geoffrey M.
0.4100% (173000)
Plattner Jacob j
0.0400% (17840)
ANAC /
Maples Kirk R
0.0200% (7220)
ANAC /
Chanda Sanjay
0.0700% (29087)
ANAC /
% ()